<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01763333</url>
  </required_header>
  <id_info>
    <org_study_id>1320.1</org_study_id>
    <secondary_id>2012-002366-12</secondary_id>
    <nct_id>NCT01763333</nct_id>
  </id_info>
  <brief_title>To Investigate the Safety, Tolerability, Pharmacokinetics and the Relative Bioavailability of BI 1026706</brief_title>
  <official_title>Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1026706 in Healthy Male Volunteers in a Partially Randomised, Single-blind, Placebo-controlled Trial, and Investigation of Relative Bioavailability of BI 1026706 (Open-label, Randomised, Four-way Cross-over)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To investigate the safety, tolerability, pharmacokinetics and the relative bioavailability of
      BI 1026706
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 8, 2013</start_date>
  <completion_date type="Actual">September 4, 2013</completion_date>
  <primary_completion_date type="Actual">September 4, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Drug Related Adverse Events</measure>
    <time_frame>From the first dose of study medication upto 15 days after the day of last intake of study medication, upto 32 days for SRD Part and 30 days for BA Part.</time_frame>
    <description>Percentage of subjects with drug related adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>−2.0 hours (h) before dosing and 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after dosing</time_frame>
    <description>Maximum measured concentration of the analyte in plasma (Cmax).
The treated set-SRD Part (TS-SRD) included all 68 subjects from the TS who participated in the SRD Part. The treated set-BA Part (TS-BA) included all 12 subjects from the TS who participated in the BA Part.
The per protocol set for the evaluation of relative bioavailability of T1 vs R1 (PPS-BA-T1-R1) included all subjects of the TS-BA who provided observations under the reference treatment (R1) or test treatment (T1) for at least one of the endpoints Cmax, AUC0-tz, or AUC0-inf,without experiencing emesis at or before two times median tmax and without important protocol violations (PVs) relevant to the statistical evaluation of pharmacokinetic (PK). The same definition applies for the analysis set PPS-BA-T2-R2, PPS-BA-R2-R1 and PPS-BA-T2-T1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax (Time From Dosing to Maximum Measured Concentration)</measure>
    <time_frame>−2.0h before dosing and 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after dosing</time_frame>
    <description>Time from dosing to maximum measured concentration (tmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf</measure>
    <time_frame>−2.0h before dosing and 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after dosing</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0− tz</measure>
    <time_frame>−2.0h before dosing and 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after dosing</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point (AUC0− tz).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 (Terminal Half-life of the Analyte in Plasma)</measure>
    <time_frame>−2.0h before dosing and 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after dosing</time_frame>
    <description>Terminal half-life of the analyte in plasma (t1/2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>f t1-t2 (SRD-Part)</measure>
    <time_frame>0-4, 4-8, 8-12, 12-24, 24-48, 48-72 hours</time_frame>
    <description>Fraction of analyte eliminated in urine from the time point t1 (0h) to time point t2 (72h) (f t1-t2).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1 BI 1026706 single rising dose part</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single rising doses of BI 1026706</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 BI 1026706 bioavailability part</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bioavailability part of BI 1026706</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1026706 Placebo</intervention_name>
    <description>Placebo to BI 1026706</description>
    <arm_group_label>1 BI 1026706 single rising dose part</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1026706</intervention_name>
    <description>different dose formulations</description>
    <arm_group_label>1 BI 1026706 single rising dose part</arm_group_label>
    <arm_group_label>2 BI 1026706 bioavailability part</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        1. healthy male subjects

        Exclusion criteria:

        1. Any relevant deviation from healthy conditions
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1320.1.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ingelheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>January 7, 2013</study_first_submitted>
  <study_first_submitted_qc>January 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2013</study_first_posted>
  <results_first_submitted>December 14, 2018</results_first_submitted>
  <results_first_submitted_qc>December 14, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 25, 2019</results_first_posted>
  <last_update_submitted>December 14, 2018</last_update_submitted>
  <last_update_submitted_qc>December 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the volunteers' pool of the Human Pharmacology Centre of Boehringer Ingelheim (BI) Pharma GmbH &amp; Co. KG, Ingelheim, Germany.Only male subjects were included because no data on reproductive toxicology was available.</recruitment_details>
      <pre_assignment_details>68 subjects were randomised for single rising dose (SRD) part &amp;12 subjects for bioavailability(BA) part of study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>BI 1026706 - Tablet 25 mg (SRD - Part)</title>
          <description>Subjects were treated in the morning with one single oral dose of 25 mg film coated tablet with 240 mL of water under fasted condition.</description>
        </group>
        <group group_id="P2">
          <title>BI 1026706 - Tablet 50 mg (SRD - Part)</title>
          <description>Subjects were treated in the morning with one single oral dose of 50 mg (2x25 mg) film coated tablet with 240 mL of water under fasted condition.</description>
        </group>
        <group group_id="P3">
          <title>BI 1026706 – Tablet 100 mg (SRD - Part)</title>
          <description>Subjects were treated in the morning with one single oral dose of 100 mg film coated tablet with 240 mL of water under fasted condition.</description>
        </group>
        <group group_id="P4">
          <title>BI 1026706 – Tablet 200 mg (SRD - Part)</title>
          <description>Subjects were treated in the morning with one single oral dose of 200 mg (2x100 mg) film coated tablet with 240 mL of water under fasted condition.</description>
        </group>
        <group group_id="P5">
          <title>BI 1026706 – Tablet 400 mg (SRD - Part)</title>
          <description>Subjects were treated in the morning with one single oral dose of 400 mg (4x100 mg) film coated tablet with 240 mL of water under fasted condition.</description>
        </group>
        <group group_id="P6">
          <title>BI 1026706 - Solution 10 mg (SRD - Part)</title>
          <description>Subjects were treated in the morning with one single oral dose of 10 mg solution under fasted condition.</description>
        </group>
        <group group_id="P7">
          <title>BI 1026706 - Solution 100 mg (SRD - Part)</title>
          <description>Subjects were treated in the morning with one single oral dose of 100 mg solution under fasted condition</description>
        </group>
        <group group_id="P8">
          <title>BI 1026706 - Solution 200 mg (SRD - Part)</title>
          <description>Subjects were treated in the morning with one single oral dose of 200 mg solution under fasted condition.</description>
        </group>
        <group group_id="P9">
          <title>BI 1026706 - Solution 400 mg (SRD - Part)</title>
          <description>Subjects were treated in the morning with one single oral dose of 400 mg solution under fasted condition.</description>
        </group>
        <group group_id="P10">
          <title>Placebo (SRD - Part)</title>
          <description>Subjects were treated in the morning with one single oral dose of matching placebo tablet and also matching placebo solution with 240 mL of water under fasted condition.</description>
        </group>
        <group group_id="P11">
          <title>R1/T1/R2/T2 (BA – Part)</title>
          <description>Subjects were treated in each of the 4 treatment periods with one single oral dose in the morning, First they were treated with 100mg film coated tablet (R1) under fasted condition, followed by 100mg film coated tablet (T1) under fed condition, 100 mg drinking solution (R2) under fasting and in the last treatment period with 100 mg drinking solution (T2) under fed condition. There was washout period of 7days between the respective treatments.</description>
        </group>
        <group group_id="P12">
          <title>T1/T2/R1/R2 (BA – Part)</title>
          <description>Subjects were treated in each of the 4 treatment periods with one single oral dose in the morning. First they were treated with 100mg film coated tablet (T1) under fed condition, followed by 100 mg drinking solution (T2) under fed condition, 100mg film coated tablet (R1) under fasted condition and in the last treatment period with 100 mg drinking solution (R2) under fasting condition. There was a washout period of 7days between the respective treatments.</description>
        </group>
        <group group_id="P13">
          <title>R2/R1/T2/T1 (BA – Part)</title>
          <description>Subjects were treated in each of the 4 treatment periods with one single oral dose in the morning, First they were treated with 100 mg drinking solution (R2) under fasting condition, followed by 100mg film coated tablet (R1) under fasted condition,100 mg drinking solution (T2) under fed condition and in the last treatment period with 100mg film coated tablet (T1) under fed condition. There was washout period of 7days between the respective treatments.</description>
        </group>
        <group group_id="P14">
          <title>T2/R2/T1/R1 (BA – Part)</title>
          <description>Subjects were treated in each of the 4 treatment periods with one single oral dose in the morning, First they were treated with 100 mg drinking solution (T2) under fed condition, followed by 100 mg drinking solution (R2) under fasting, 100mg film coated tablet (T1) under fed condition and in the last treatment period with 100mg film coated tablet (R1) under fasted condition. There was washout period of 7days between the respective treatments.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="18"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="3"/>
                <participants group_id="P13" count="3"/>
                <participants group_id="P14" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="18"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="3"/>
                <participants group_id="P13" count="3"/>
                <participants group_id="P14" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BI 1026706 - Tablet 25 mg (SRD - Part)</title>
          <description>Subjects were treated in the morning with one single oral dose of 25 mg film coated tablet with 240 mL of water under fasted condition.</description>
        </group>
        <group group_id="B2">
          <title>BI 1026706 - Tablet 50 mg (SRD - Part)</title>
          <description>Subjects were treated in the morning with one single oral dose of 50 mg (2x25 mg) film coated tablet with 240 mL of water under fasted condition.</description>
        </group>
        <group group_id="B3">
          <title>BI 1026706 – Tablet 100 mg (SRD - Part)</title>
          <description>Subjects were treated in the morning with one single oral dose of 100 mg film coated tablet with 240 mL of water under fasted condition.</description>
        </group>
        <group group_id="B4">
          <title>BI 1026706 – Tablet 200 mg (SRD - Part)</title>
          <description>Subjects were treated in the morning with one single oral dose of 200 mg (2x100 mg) film coated tablet with 240 mL of water under fasted condition.</description>
        </group>
        <group group_id="B5">
          <title>BI 1026706 – Tablet 400 mg (SRD - Part)</title>
          <description>Subjects were treated in the morning with one single oral dose of 400 mg (4x100 mg) film coated tablet with 240 mL of water under fasted condition.</description>
        </group>
        <group group_id="B6">
          <title>BI 1026706 - Solution 10 mg (SRD - Part)</title>
          <description>Subjects were treated in the morning with one single oral dose of 10 mg solution under fasted condition.</description>
        </group>
        <group group_id="B7">
          <title>BI 1026706 - Solution 100 mg (SRD - Part)</title>
          <description>Subjects were treated in the morning with one single oral dose of 100 mg solution under fasted condition</description>
        </group>
        <group group_id="B8">
          <title>BI 1026706 - Solution 200 mg (SRD - Part)</title>
          <description>Subjects were treated in the morning with one single oral dose of 200 mg solution under fasted condition.</description>
        </group>
        <group group_id="B9">
          <title>BI 1026706 - Solution 400 mg (SRD - Part)</title>
          <description>Subjects were treated in the morning with one single oral dose of 400 mg solution under fasted condition.</description>
        </group>
        <group group_id="B10">
          <title>Placebo (SRD - Part)</title>
          <description>Subjects were treated in the morning with one single oral dose of matching placebo tablet and also matching placebo solution with 240 mL of water under fasted condition.</description>
        </group>
        <group group_id="B11">
          <title>R1/T1/R2/T2 (BA – Part)</title>
          <description>Subjects were treated in each of the 4 treatment periods with one single oral dose in the morning, First they were treated with 100mg film coated tablet (R1) under fasted condition, followed by 100mg film coated tablet (T1) under fed condition, 100 mg drinking solution (R2) under fasting and in the last treatment period with 100 mg drinking solution (T2) under fed condition. There was washout period of 7days between the respective treatments.</description>
        </group>
        <group group_id="B12">
          <title>T1/T2/R1/R2 (BA – Part)</title>
          <description>Subjects were treated in each of the 4 treatment periods with one single oral dose in the morning. First they were treated with 100mg film coated tablet (T1) under fed condition, followed by 100 mg drinking solution (T2) under fed condition, 100mg film coated tablet (R1) under fasted condition and in the last treatment period with 100 mg drinking solution (R2) under fasting condition. There was a washout period of 7days between the respective treatments.</description>
        </group>
        <group group_id="B13">
          <title>R2/R1/T2/T1 (BA – Part)</title>
          <description>Subjects were treated in each of the 4 treatment periods with one single oral dose in the morning, First they were treated with 100 mg drinking solution (R2) under fasting condition, followed by 100mg film coated tablet (R1) under fasted condition,100 mg drinking solution (T2) under fed condition and in the last treatment period with 100mg film coated tablet (T1) under fed condition. There was washout period of 7days between the respective treatments.</description>
        </group>
        <group group_id="B14">
          <title>T2/R2/T1/R1 (BA – Part)</title>
          <description>Subjects were treated in each of the 4 treatment periods with one single oral dose in the morning, First they were treated with 100 mg drinking solution (T2) under fed condition, followed by 100 mg drinking solution (R2) under fasting, 100mg film coated tablet (T1) under fed condition and in the last treatment period with 100mg film coated tablet (R1) under fasted condition. There was washout period of 7days between the respective treatments.</description>
        </group>
        <group group_id="B15">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="4"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="5"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="5"/>
            <count group_id="B10" value="18"/>
            <count group_id="B11" value="3"/>
            <count group_id="B12" value="3"/>
            <count group_id="B13" value="3"/>
            <count group_id="B14" value="3"/>
            <count group_id="B15" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.8" spread="4.2"/>
                    <measurement group_id="B2" value="39.0" spread="5.8"/>
                    <measurement group_id="B3" value="35.5" spread="7.1"/>
                    <measurement group_id="B4" value="39.5" spread="7.3"/>
                    <measurement group_id="B5" value="42.0" spread="5.7"/>
                    <measurement group_id="B6" value="39.7" spread="8.0"/>
                    <measurement group_id="B7" value="43.4" spread="7.8"/>
                    <measurement group_id="B8" value="35.7" spread="9.2"/>
                    <measurement group_id="B9" value="32.4" spread="12.0"/>
                    <measurement group_id="B10" value="35.9" spread="7.2"/>
                    <measurement group_id="B11" value="32.7" spread="12.4"/>
                    <measurement group_id="B12" value="27.0" spread="3.6"/>
                    <measurement group_id="B13" value="26.7" spread="4.9"/>
                    <measurement group_id="B14" value="27.0" spread="5.6"/>
                    <measurement group_id="B15" value="36.3" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="18"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="3"/>
                    <measurement group_id="B14" value="3"/>
                    <measurement group_id="B15" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Drug Related Adverse Events</title>
        <description>Percentage of subjects with drug related adverse events.</description>
        <time_frame>From the first dose of study medication upto 15 days after the day of last intake of study medication, upto 32 days for SRD Part and 30 days for BA Part.</time_frame>
        <population>The treated set (TS) included all subjects who were documented to have taken at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>BI 1026706 - Tablet 25 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 25 mg film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>BI 1026706 - Tablet 50 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 50 mg (2x25 mg) film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O3">
            <title>BI 1026706 – Tablet 100 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 100 mg film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O4">
            <title>BI 1026706 – Tablet 200 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 200 mg (2x100 mg) film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O5">
            <title>BI 1026706 – Tablet 400 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 400 mg (4x100 mg) film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O6">
            <title>BI 1026706 - Solution 10 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 10 mg solution under fasted condition.</description>
          </group>
          <group group_id="O7">
            <title>BI 1026706 - Solution 100 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 100 mg solution under fasted condition</description>
          </group>
          <group group_id="O8">
            <title>BI 1026706 - Solution 200 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 200 mg solution under fasted condition.</description>
          </group>
          <group group_id="O9">
            <title>BI 1026706 - Solution 400 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 400 mg solution under fasted condition.</description>
          </group>
          <group group_id="O10">
            <title>Placebo (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of matching placebo tablet and also matching placebo solution with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O11">
            <title>BI 1026706 - Solution 100 mg Fasted (R2)</title>
            <description>Subjects were treated with 100 mg drinking solution (R2) under fasting condition.</description>
          </group>
          <group group_id="O12">
            <title>BI 1026706 - 100 mg Solution Fed (T2)</title>
            <description>Subjects were treated with 100 mg drinking solution (T2) under fed condition.</description>
          </group>
          <group group_id="O13">
            <title>BI 1026706 - Tablet 100 mg Fasted (R1)</title>
            <description>Subjects were treated with 100mg film coated tablet (R1) under fasted condition.</description>
          </group>
          <group group_id="O14">
            <title>BI 1026706 - Tablet 100 mg Fed (T1)</title>
            <description>Subjects were treated with 100mg film coated tablet (T1) under fed condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Drug Related Adverse Events</title>
          <description>Percentage of subjects with drug related adverse events.</description>
          <population>The treated set (TS) included all subjects who were documented to have taken at least one dose of study medication.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="18"/>
                <count group_id="O11" value="11"/>
                <count group_id="O12" value="12"/>
                <count group_id="O13" value="12"/>
                <count group_id="O14" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="25.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="20.0"/>
                    <measurement group_id="O8" value="16.7"/>
                    <measurement group_id="O9" value="60.0"/>
                    <measurement group_id="O10" value="22.2"/>
                    <measurement group_id="O11" value="0.0"/>
                    <measurement group_id="O12" value="8.3"/>
                    <measurement group_id="O13" value="16.7"/>
                    <measurement group_id="O14" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax</title>
        <description>Maximum measured concentration of the analyte in plasma (Cmax).
The treated set-SRD Part (TS-SRD) included all 68 subjects from the TS who participated in the SRD Part. The treated set-BA Part (TS-BA) included all 12 subjects from the TS who participated in the BA Part.
The per protocol set for the evaluation of relative bioavailability of T1 vs R1 (PPS-BA-T1-R1) included all subjects of the TS-BA who provided observations under the reference treatment (R1) or test treatment (T1) for at least one of the endpoints Cmax, AUC0-tz, or AUC0-inf,without experiencing emesis at or before two times median tmax and without important protocol violations (PVs) relevant to the statistical evaluation of pharmacokinetic (PK). The same definition applies for the analysis set PPS-BA-T2-R2, PPS-BA-R2-R1 and PPS-BA-T2-T1.</description>
        <time_frame>−2.0 hours (h) before dosing and 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after dosing</time_frame>
        <population>TS-SRD, TS-BA, PPS-DP, PPS-BA-T1-R1, PPS-BA-T2-R2, PPS-BA-R2-R1 and PPS-BA-T2-T1</population>
        <group_list>
          <group group_id="O1">
            <title>BI 1026706 - Tablet 25 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 25 mg film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>BI 1026706 - Tablet 50 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 50 mg (2x25 mg) film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O3">
            <title>BI 1026706 – Tablet 100 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 100 mg film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O4">
            <title>BI 1026706 – Tablet 200 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 200 mg (2x100 mg) film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O5">
            <title>BI 1026706 – Tablet 400 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 400 mg (4x100 mg) film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O6">
            <title>BI 1026706 - Solution 10 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 10 mg solution under fasted condition.</description>
          </group>
          <group group_id="O7">
            <title>BI 1026706 - Solution 100 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 100 mg solution under fasted condition</description>
          </group>
          <group group_id="O8">
            <title>BI 1026706 - Solution 200 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 200 mg solution under fasted condition.</description>
          </group>
          <group group_id="O9">
            <title>BI 1026706 - Solution 400 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 400 mg solution under fasted condition.</description>
          </group>
          <group group_id="O10">
            <title>BI 1026706 - Solution 100 mg Fasted (R2)</title>
            <description>Subjects were treated with 100 mg drinking solution (R2) under fasting condition.</description>
          </group>
          <group group_id="O11">
            <title>BI 1026706 - 100 mg Solution Fed (T2)</title>
            <description>Subjects were treated with 100 mg drinking solution (T2) under fed condition.</description>
          </group>
          <group group_id="O12">
            <title>BI 1026706 - Tablet 100 mg Fasted (R1)</title>
            <description>Subjects were treated with 100mg film coated tablet (R1) under fasted condition.</description>
          </group>
          <group group_id="O13">
            <title>BI 1026706 - Tablet 100 mg Fed (T1)</title>
            <description>Subjects were treated with 100mg film coated tablet (T1) under fed condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Maximum measured concentration of the analyte in plasma (Cmax).
The treated set-SRD Part (TS-SRD) included all 68 subjects from the TS who participated in the SRD Part. The treated set-BA Part (TS-BA) included all 12 subjects from the TS who participated in the BA Part.
The per protocol set for the evaluation of relative bioavailability of T1 vs R1 (PPS-BA-T1-R1) included all subjects of the TS-BA who provided observations under the reference treatment (R1) or test treatment (T1) for at least one of the endpoints Cmax, AUC0-tz, or AUC0-inf,without experiencing emesis at or before two times median tmax and without important protocol violations (PVs) relevant to the statistical evaluation of pharmacokinetic (PK). The same definition applies for the analysis set PPS-BA-T2-R2, PPS-BA-R2-R1 and PPS-BA-T2-T1.</description>
          <population>TS-SRD, TS-BA, PPS-DP, PPS-BA-T1-R1, PPS-BA-T2-R2, PPS-BA-R2-R1 and PPS-BA-T2-T1</population>
          <units>nanomoles Per Litre (nmol/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="11"/>
                <count group_id="O11" value="12"/>
                <count group_id="O12" value="12"/>
                <count group_id="O13" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117" spread="33.1"/>
                    <measurement group_id="O2" value="268" spread="42.9"/>
                    <measurement group_id="O3" value="623" spread="40.9"/>
                    <measurement group_id="O4" value="728" spread="26.8"/>
                    <measurement group_id="O5" value="1430" spread="80.0"/>
                    <measurement group_id="O6" value="112" spread="32.9"/>
                    <measurement group_id="O7" value="1150" spread="47.1"/>
                    <measurement group_id="O8" value="2210" spread="28.0"/>
                    <measurement group_id="O9" value="3090" spread="24.8"/>
                    <measurement group_id="O10" value="1340" spread="32.0"/>
                    <measurement group_id="O11" value="706" spread="33.5"/>
                    <measurement group_id="O12" value="560" spread="34.8"/>
                    <measurement group_id="O13" value="651" spread="34.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>This was non confirmatory testing (Single dose). Dose proportionality of tablets for Cmax was analysed. The per protocol set for the evaluation of dose proportionality (PPS-DP) was used. This set included all subjects of the TS-SRD who provided at least one observation for at least one of the endpoints Cmax, AUC0-tz, AUC0-∞, or Aet1-t2, without experiencing emesis at or before 2 times median tmax and without important PVs relevant to the statistical evaluation of PK.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>0.8728</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6942</ci_lower_limit>
            <ci_upper_limit>1.0513</ci_upper_limit>
            <estimate_desc>Dose proportionality was explored using the power model (ANCOVA). The perfect dose proportionality would correspond to a slope β of 1. PK endpoints on the log-transformed scale.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>This was non confirmatory testing (Single dose). Dose proportionality of solution for Cmax was analysed. The per protocol set for the evaluation of dose proportionality (PPS-DP) was used. This set included all subjects of the TS-SRD who provided at least one observation for at least one of the endpoints Cmax, AUC0-tz, AUC0-∞, or Aet1-t2, without experiencing emesis at or before 2 times median tmax and without important PVs relevant to the statistical evaluation of PK.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>0.9341</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8277</ci_lower_limit>
            <ci_upper_limit>1.0405</ci_upper_limit>
            <estimate_desc>Dose proportionality was explored using the power model (ANCOVA). The perfect dose proportionality would correspond to a slope β of 1. PK endpoints on the log-transformed scale.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O12</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <groups_desc>Relative bioavailability comparison Tab. fed (T1): Tab. fasted (R1) for Cmax. The per protocol set for the evaluation of relative bioavailability of T1 vs R1 (PPS-BA-T1-R1) was used.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The pharmacokinetic parameters were log transformed (natural logarithm) prior to fitting the ANOVA model. The difference between the expected means of the 2 treatments of interest for each pairwise comparison were estimated by the difference in the corresponding Least Square Means (point estimate) and two-sided 90% confidence intervals based on the t-distribution were computed. These quantities were then back-transformed to the original scale to give the point estimator (geometric mean).</non_inferiority_desc>
            <param_type>gMean ratio</param_type>
            <param_value>112.74</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95.579</ci_lower_limit>
            <ci_upper_limit>132.993</ci_upper_limit>
            <estimate_desc>Adjusted gMean ratio.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <groups_desc>Relative bioavailability comparison Sol. fed (T2) : Sol. fasted (R2) for Cmax. The per protocol set for the evaluation of relative bioavailability of T2 vs R2 (PPS-BA-T2-R2) was used.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The pharmacokinetic parameters were log transformed (natural logarithm) prior to fitting the ANOVA model. The difference between the expected means of the 2 treatments of interest for each pairwise comparison were estimated by the difference in the corresponding Least Square Means (point estimate) and two-sided 90% confidence intervals based on the t-distribution were computed. These quantities were then back-transformed to the original scale to give the point estimator (geometric mean).</non_inferiority_desc>
            <param_type>gMean ratio</param_type>
            <param_value>52.66</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>40.488</ci_lower_limit>
            <ci_upper_limit>68.499</ci_upper_limit>
            <estimate_desc>Adjusted gMean ratio.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <groups_desc>Relative bioavailability comparison Sol. fasted (R2): Tab. fasted (R1) for Cmax. The per protocol set for the evaluation of relative bioavailability of R2 vs R1 (PPS-BA-R2-R1) was used.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The pharmacokinetic parameters were log transformed (natural logarithm) prior to fitting the ANOVA model. The difference between the expected means of the 2 treatments of interest for each pairwise comparison were estimated by the difference in the corresponding Least Square Means (point estimate) and two-sided 90% confidence intervals based on the t-distribution were computed. These quantities were then back-transformed to the original scale to give the point estimator (geometric mean).</non_inferiority_desc>
            <param_type>gMean ratio</param_type>
            <param_value>239.63</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>197.445</ci_lower_limit>
            <ci_upper_limit>290.830</ci_upper_limit>
            <estimate_desc>Adjusted gMean ratio.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <groups_desc>Relative bioavailability comparison Sol. fed (T2): Tab. fed (T1) for Cmax. The per protocol set for the evaluation of relative bioavailability of T2 vs T1 (PPS-BA-T2-T1) was used.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The pharmacokinetic parameters were log transformed (natural logarithm) prior to fitting the ANOVA model. The difference between the expected means of the 2 treatments of interest for each pairwise comparison were estimated by the difference in the corresponding Least Square Means (point estimate) and two-sided 90% confidence intervals based on the t-distribution were computed. These quantities were then back-transformed to the original scale to give the point estimator (geometric mean).</non_inferiority_desc>
            <param_type>gMean ratio</param_type>
            <param_value>105.47</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>85.427</ci_lower_limit>
            <ci_upper_limit>130.208</ci_upper_limit>
            <estimate_desc>Adjusted gMean ratio.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax (Time From Dosing to Maximum Measured Concentration)</title>
        <description>Time from dosing to maximum measured concentration (tmax).</description>
        <time_frame>−2.0h before dosing and 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after dosing</time_frame>
        <population>The treated set-SRD Part (TS-SRD) included all 68 subjects from the TS who participated in the SRD Part. The treated set-BA Part (TS-BA) included all 12 subjects from the TS who participated in the BA Part.</population>
        <group_list>
          <group group_id="O1">
            <title>BI 1026706 - Tablet 25 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 25 mg film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>BI 1026706 - Tablet 50 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 50 mg (2x25 mg) film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O3">
            <title>BI 1026706 – Tablet 100 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 100 mg film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O4">
            <title>BI 1026706 – Tablet 200 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 200 mg (2x100 mg) film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O5">
            <title>BI 1026706 – Tablet 400 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 400 mg (4x100 mg) film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O6">
            <title>BI 1026706 - Solution 10 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 10 mg solution under fasted condition.</description>
          </group>
          <group group_id="O7">
            <title>BI 1026706 - Solution 100 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 100 mg solution under fasted condition</description>
          </group>
          <group group_id="O8">
            <title>BI 1026706 - Solution 200 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 200 mg solution under fasted condition.</description>
          </group>
          <group group_id="O9">
            <title>BI 1026706 - Solution 400 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 400 mg solution under fasted condition.</description>
          </group>
          <group group_id="O10">
            <title>BI 1026706 - Solution 100 mg Fasted (R2)</title>
            <description>Subjects were treated with 100 mg drinking solution (R2) under fasting condition.</description>
          </group>
          <group group_id="O11">
            <title>BI 1026706 - 100 mg Solution Fed (T2)</title>
            <description>Subjects were treated with 100 mg drinking solution (T2) under fed condition.</description>
          </group>
          <group group_id="O12">
            <title>BI 1026706 - Tablet 100 mg Fasted (R1)</title>
            <description>Subjects were treated with 100mg film coated tablet (R1) under fasted condition.</description>
          </group>
          <group group_id="O13">
            <title>BI 1026706 - Tablet 100 mg Fed (T1)</title>
            <description>Subjects were treated with 100mg film coated tablet (T1) under fed condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax (Time From Dosing to Maximum Measured Concentration)</title>
          <description>Time from dosing to maximum measured concentration (tmax).</description>
          <population>The treated set-SRD Part (TS-SRD) included all 68 subjects from the TS who participated in the SRD Part. The treated set-BA Part (TS-BA) included all 12 subjects from the TS who participated in the BA Part.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="11"/>
                <count group_id="O11" value="12"/>
                <count group_id="O12" value="12"/>
                <count group_id="O13" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" lower_limit="0.75" upper_limit="4.07"/>
                    <measurement group_id="O2" value="1.51" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O3" value="1.75" lower_limit="0.73" upper_limit="4.02"/>
                    <measurement group_id="O4" value="1.25" lower_limit="0.76" upper_limit="4.02"/>
                    <measurement group_id="O5" value="2.23" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O6" value="0.63" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O7" value="0.50" lower_limit="0.50" upper_limit="0.76"/>
                    <measurement group_id="O8" value="0.75" lower_limit="0.42" upper_limit="0.75"/>
                    <measurement group_id="O9" value="0.75" lower_limit="0.42" upper_limit="1.00"/>
                    <measurement group_id="O10" value="0.52" lower_limit="0.50" upper_limit="0.75"/>
                    <measurement group_id="O11" value="0.75" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O12" value="1.74" lower_limit="0.75" upper_limit="3.02"/>
                    <measurement group_id="O13" value="1.26" lower_limit="0.50" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-inf</title>
        <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf).</description>
        <time_frame>−2.0h before dosing and 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after dosing</time_frame>
        <population>TS-SRD, TS-BA, PPS-DP, PPS-BA-T1-R1, PPS-BA-T2-R2, PPS-BA-R2-R1 and PPS-BA-T2-T1</population>
        <group_list>
          <group group_id="O1">
            <title>BI 1026706 - Tablet 25 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 25 mg film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>BI 1026706 - Tablet 50 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 50 mg (2x25 mg) film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O3">
            <title>BI 1026706 – Tablet 100 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 100 mg film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O4">
            <title>BI 1026706 – Tablet 200 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 200 mg (2x100 mg) film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O5">
            <title>BI 1026706 – Tablet 400 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 400 mg (4x100 mg) film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O6">
            <title>BI 1026706 - Solution 10 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 10 mg solution under fasted condition.</description>
          </group>
          <group group_id="O7">
            <title>BI 1026706 - Solution 100 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 100 mg solution under fasted condition</description>
          </group>
          <group group_id="O8">
            <title>BI 1026706 - Solution 200 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 200 mg solution under fasted condition.</description>
          </group>
          <group group_id="O9">
            <title>BI 1026706 - Solution 400 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 400 mg solution under fasted condition.</description>
          </group>
          <group group_id="O10">
            <title>BI 1026706 - Solution 100 mg Fasted (R2)</title>
            <description>Subjects were treated with 100 mg drinking solution (R2) under fasting condition.</description>
          </group>
          <group group_id="O11">
            <title>BI 1026706 - 100 mg Solution Fed (T2)</title>
            <description>Subjects were treated with 100 mg drinking solution (T2) under fed condition.</description>
          </group>
          <group group_id="O12">
            <title>BI 1026706 - Tablet 100 mg Fasted (R1)</title>
            <description>Subjects were treated with 100mg film coated tablet (R1) under fasted condition.</description>
          </group>
          <group group_id="O13">
            <title>BI 1026706 - Tablet 100 mg Fed (T1)</title>
            <description>Subjects were treated with 100mg film coated tablet (T1) under fed condition.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf</title>
          <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf).</description>
          <population>TS-SRD, TS-BA, PPS-DP, PPS-BA-T1-R1, PPS-BA-T2-R2, PPS-BA-R2-R1 and PPS-BA-T2-T1</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="11"/>
                <count group_id="O11" value="12"/>
                <count group_id="O12" value="12"/>
                <count group_id="O13" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="768" spread="28.6"/>
                    <measurement group_id="O2" value="1690" spread="51.8"/>
                    <measurement group_id="O3" value="3990" spread="30.9"/>
                    <measurement group_id="O4" value="4040" spread="29.4"/>
                    <measurement group_id="O5" value="8900" spread="85.1"/>
                    <measurement group_id="O6" value="428" spread="41.9"/>
                    <measurement group_id="O7" value="3220" spread="43.5"/>
                    <measurement group_id="O8" value="7790" spread="26.9"/>
                    <measurement group_id="O9" value="11300" spread="28.3"/>
                    <measurement group_id="O10" value="4590" spread="33.1"/>
                    <measurement group_id="O11" value="3380" spread="28.6"/>
                    <measurement group_id="O12" value="3270" spread="28.3"/>
                    <measurement group_id="O13" value="2930" spread="40.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>This was non confirmatory testing (Single dose).Dose proportionality of tablets for AUC0-inf was analysed.The per protocol set for the evaluation of dose proportionality (PPS-DP) was used. This set included all subjects of the TS-SRD who provided at least one observation for at least one of the endpoints Cmax, AUC0-tz, AUC0-∞, or Aet1-t2, without experiencing emesis at or before 2 times median tmax and without important PVs relevant to the statistical evaluation of PK.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>0.8341</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6485</ci_lower_limit>
            <ci_upper_limit>1.0198</ci_upper_limit>
            <estimate_desc>Dose proportionality was explored using the power model (ANCOVA). The perfect dose proportionality would correspond to a slope β of 1. PK endpoints on the log-transformed scale.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>This was non confirmatory testing (Single dose).Dose proportionality of solution for AUC0-inf was analysed. The per protocol set for the evaluation of dose proportionality (PPS-DP) was used. This set included all subjects of the TS-SRD who provided at least one observation for at least one of the endpoints Cmax, AUC0-tz, AUC0-∞, or Aet1-t2, without experiencing emesis at or before 2 times median tmax and without important PVs relevant to the statistical evaluation of PK.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>0.9149</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8059</ci_lower_limit>
            <ci_upper_limit>1.0239</ci_upper_limit>
            <estimate_desc>Dose proportionality was explored using the power model (ANCOVA). The perfect dose proportionality would correspond to a slope β of 1. PK endpoints on the log-transformed scale.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O12</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <groups_desc>Relative bioavailability comparison Tab. fed (T1): Tab. fasted (R1) for AUC0-inf. The per protocol set for the evaluation of relative bioavailability of T1 vs R1 (PPS-BA-T1-R1) was used.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The pharmacokinetic parameters were log transformed (natural logarithm) prior to fitting the ANOVA model. The difference between the expected means of the 2 treatments of interest for each pairwise comparison were estimated by the difference in the corresponding Least Square Means (point estimate) and two-sided 90% confidence intervals based on the t-distribution were computed. These quantities were then back-transformed to the original scale to give the point estimator (geometric mean).</non_inferiority_desc>
            <param_type>gMean Ratio</param_type>
            <param_value>86.61</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>76.529</ci_lower_limit>
            <ci_upper_limit>98.029</ci_upper_limit>
            <estimate_desc>Adjusted gMean ratio.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <groups_desc>Relative bioavailability comparison Sol. fed (T2) : Sol. fasted (R2) for AUC0-inf.The per protocol set for the evaluation of relative bioavailability of T2 vs R2 (PPS-BA-T2-R2) was used.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The pharmacokinetic parameters were log transformed (natural logarithm) prior to fitting the ANOVA model. The difference between the expected means of the 2 treatments of interest for each pairwise comparison were estimated by the difference in the corresponding Least Square Means (point estimate) and two-sided 90% confidence intervals based on the t-distribution were computed. These quantities were then back-transformed to the original scale to give the point estimator (geometric mean).</non_inferiority_desc>
            <param_type>gMean ratio</param_type>
            <param_value>74.44</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>66.322</ci_lower_limit>
            <ci_upper_limit>83.562</ci_upper_limit>
            <estimate_desc>Adjusted gMean ratio.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <groups_desc>Relative bioavailability comparison Sol. fasted (R2): Tab. fasted (R1) for AUC0-inf.The per protocol set for the evaluation of relative bioavailability of R2 vs R1 (PPS-BA-R2-R1) was used.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The pharmacokinetic parameters were log transformed (natural logarithm) prior to fitting the ANOVA model. The difference between the expected means of the 2 treatments of interest for each pairwise comparison were estimated by the difference in the corresponding Least Square Means (point estimate) and two-sided 90% confidence intervals based on the t-distribution were computed. These quantities were then back-transformed to the original scale to give the point estimator (geometric mean).</non_inferiority_desc>
            <param_type>gMean ratio</param_type>
            <param_value>137.25</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>119.708</ci_lower_limit>
            <ci_upper_limit>157.353</ci_upper_limit>
            <estimate_desc>Adjusted gMean ratio.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <groups_desc>Relative bioavailability comparison Sol. fed (T2): Tab. fed (T1) for AUC0-inf.The per protocol set for the evaluation of relative bioavailability of T2 vs T1 (PPS-BA-T2-T1) was used.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The pharmacokinetic parameters were log transformed (natural logarithm) prior to fitting the ANOVA model. The difference between the expected means of the 2 treatments of interest for each pairwise comparison were estimated by the difference in the corresponding Least Square Means (point estimate) and two-sided 90% confidence intervals based on the t-distribution were computed. These quantities were then back-transformed to the original scale to give the point estimator (geometric mean).</non_inferiority_desc>
            <param_type>gMean ratio</param_type>
            <param_value>116.48</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>111.462</ci_lower_limit>
            <ci_upper_limit>121.724</ci_upper_limit>
            <estimate_desc>Adjusted gMean ratio.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0− tz</title>
        <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point (AUC0− tz).</description>
        <time_frame>−2.0h before dosing and 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after dosing</time_frame>
        <population>TS-SRD, TS-BA, PPS-DP, PPS-BA-T1-R1, PPS-BA-T2-R2, PPS-BA-R2-R1 and PPS-BA-T2-T1</population>
        <group_list>
          <group group_id="O1">
            <title>BI 1026706 - Tablet 25 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 25 mg film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>BI 1026706 - Tablet 50 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 50 mg (2x25 mg) film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O3">
            <title>BI 1026706 – Tablet 100 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 100 mg film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O4">
            <title>BI 1026706 – Tablet 200 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 200 mg (2x100 mg) film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O5">
            <title>BI 1026706 – Tablet 400 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 400 mg (4x100 mg) film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O6">
            <title>BI 1026706 - Solution 10 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 10 mg solution under fasted condition.</description>
          </group>
          <group group_id="O7">
            <title>BI 1026706 - Solution 100 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 100 mg solution under fasted condition</description>
          </group>
          <group group_id="O8">
            <title>BI 1026706 - Solution 200 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 200 mg solution under fasted condition.</description>
          </group>
          <group group_id="O9">
            <title>BI 1026706 - Solution 400 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 400 mg solution under fasted condition.</description>
          </group>
          <group group_id="O10">
            <title>BI 1026706 - Solution 100 mg Fasted (R2)</title>
            <description>Subjects were treated with 100 mg drinking solution (R2) under fasting condition.</description>
          </group>
          <group group_id="O11">
            <title>BI 1026706 - 100 mg Solution Fed (T2)</title>
            <description>Subjects were treated with 100 mg drinking solution (T2) under fed condition.</description>
          </group>
          <group group_id="O12">
            <title>BI 1026706 - Tablet 100 mg Fasted (R1)</title>
            <description>Subjects were treated with 100mg film coated tablet (R1) under fasted condition.</description>
          </group>
          <group group_id="O13">
            <title>BI 1026706 - Tablet 100 mg Fed (T1)</title>
            <description>Subjects were treated with 100mg film coated tablet (T1) under fed condition.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0− tz</title>
          <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point (AUC0− tz).</description>
          <population>TS-SRD, TS-BA, PPS-DP, PPS-BA-T1-R1, PPS-BA-T2-R2, PPS-BA-R2-R1 and PPS-BA-T2-T1</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="11"/>
                <count group_id="O11" value="12"/>
                <count group_id="O12" value="12"/>
                <count group_id="O13" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="741" spread="25.2"/>
                    <measurement group_id="O2" value="1670" spread="51.8"/>
                    <measurement group_id="O3" value="3950" spread="30.5"/>
                    <measurement group_id="O4" value="3990" spread="28.6"/>
                    <measurement group_id="O5" value="8830" spread="85.3"/>
                    <measurement group_id="O6" value="403" spread="44.0"/>
                    <measurement group_id="O7" value="3170" spread="27.0"/>
                    <measurement group_id="O8" value="7710" spread="27.0"/>
                    <measurement group_id="O9" value="11300" spread="28.3"/>
                    <measurement group_id="O10" value="4550" spread="33.3"/>
                    <measurement group_id="O11" value="3360" spread="28.9"/>
                    <measurement group_id="O12" value="3240" spread="28.3"/>
                    <measurement group_id="O13" value="2900" spread="40.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>This was non confirmatory testing (Single dose). Dose proportionality of tablets for AUC 0− tz was analysed. The per protocol set for the evaluation of dose proportionality (PPS-DP) was used. This set included all subjects of the TS-SRD who provided at least one observation for at least one of the endpoints Cmax, AUC0-tz, AUC0-∞, or Aet1-t2, without experiencing emesis at or before 2 times median tmax and without important PVs relevant to the statistical evaluation of PK.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>0.8428</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6580</ci_lower_limit>
            <ci_upper_limit>1.0275</ci_upper_limit>
            <estimate_desc>Dose proportionality was explored using the power model (ANCOVA). The perfect dose proportionality would correspond to a slope β of 1. PK endpoints on the log-transformed scale.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>This was non confirmatory testing (Single dose). Dose proportionality of solution for AUC0-tz was analysed. The per protocol set for the evaluation of dose proportionality (PPS-DP) was used. This set included all subjects of the TS-SRD who provided at least one observation for at least one of the endpoints Cmax, AUC0-tz, AUC0-∞, or Aet1-t2, without experiencing emesis at or before 2 times median tmax and without important PVs relevant to the statistical evaluation of PK.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>0.9307</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8187</ci_lower_limit>
            <ci_upper_limit>1.0426</ci_upper_limit>
            <estimate_desc>Dose proportionality was explored using the power model (ANCOVA). The perfect dose proportionality would correspond to a slope β of 1.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O12</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <groups_desc>Relative bioavailability comparison Tab. fed (T1) : Tab. fasted (R1) for AUC 0-tz. The per protocol set for the evaluation of relative bioavailability of T1 vs R1 (PPS-BA-T1-R1) was used.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The pharmacokinetic parameters were log transformed (natural logarithm) prior to fitting the ANOVA model. The difference between the expected means of the 2 treatments of interest for each pairwise comparison were estimated by the difference in the corresponding Least Square Means (point estimate) and two-sided 90% confidence intervals based on the t-distribution were computed. These quantities were then back-transformed to the original scale to give the point estimator (geometric mean)</non_inferiority_desc>
            <param_type>gMean Ratio</param_type>
            <param_value>86.16</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>75.735</ci_lower_limit>
            <ci_upper_limit>98.027</ci_upper_limit>
            <estimate_desc>Adjusted geometric mean (gMean) ratio.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <groups_desc>Relative bioavailability comparison Sol. fed (T2) : Sol. fasted (R2) for AUC 0-tz.The per protocol set for the evaluation of relative bioavailability of T2 vs R2 (PPS-BA-T2-R2) was used.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The pharmacokinetic parameters were log transformed (natural logarithm) prior to fitting the ANOVA model. The difference between the expected means of the 2 treatments of interest for each pairwise comparison were estimated by the difference in the corresponding Least Square Means (point estimate) and two-sided 90% confidence intervals based on the t-distribution were computed. These quantities were then back-transformed to the original scale to give the point estimator (geometric mean)</non_inferiority_desc>
            <param_type>gMean ratio</param_type>
            <param_value>74.42</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>65.979</ci_lower_limit>
            <ci_upper_limit>83.941</ci_upper_limit>
            <estimate_desc>Adjusted gMean ratio.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <groups_desc>Relative bioavailability comparison Sol. fasted (R2): Tab. fasted (R1) for AUC 0-tz.The per protocol set for the evaluation of relative bioavailability of R2 vs R1(PPS-BA-R2-R1) was used.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The pharmacokinetic parameters were log transformed (natural logarithm) prior to fitting the ANOVA model. The difference between the expected means of the 2 treatments of interest for each pairwise comparison were estimated by the difference in the corresponding Least Square Means (point estimate) and two-sided 90% confidence intervals based on the t-distribution were computed. These quantities were then back-transformed to the original scale to give the point estimator (geometric mean).</non_inferiority_desc>
            <param_type>gMean ratio</param_type>
            <param_value>137.20</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>119.611</ci_lower_limit>
            <ci_upper_limit>157.374</ci_upper_limit>
            <estimate_desc>Adjusted gMean ratio.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <groups_desc>Relative bioavailability comparison Sol. fed (T2): Tab. fed (T1) for AUC 0-tz.The per protocol set for the evaluation of relative bioavailability of T2 vs T1 (PPS-BA-T2-T1) was used.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The pharmacokinetic parameters were log transformed (natural logarithm) prior to fitting the ANOVA model. The difference between the expected means of the 2 treatments of interest for each pairwise comparison were estimated by the difference in the corresponding Least Square Means (point estimate) and two-sided 90% confidence intervals based on the t-distribution were computed. These quantities were then back-transformed to the original scale to give the point estimator (geometric mean).</non_inferiority_desc>
            <param_type>gMean ratio</param_type>
            <param_value>116.83</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>111.814</ci_lower_limit>
            <ci_upper_limit>122.079</ci_upper_limit>
            <estimate_desc>Adjusted gMean ratio.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t1/2 (Terminal Half-life of the Analyte in Plasma)</title>
        <description>Terminal half-life of the analyte in plasma (t1/2).</description>
        <time_frame>−2.0h before dosing and 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after dosing</time_frame>
        <population>TS-SRD and TS-BA</population>
        <group_list>
          <group group_id="O1">
            <title>BI 1026706 - Tablet 25 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 25 mg film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>BI 1026706 - Tablet 50 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 50 mg (2x25 mg) film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O3">
            <title>BI 1026706 – Tablet 100 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 100 mg film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O4">
            <title>BI 1026706 – Tablet 200 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 200 mg (2x100 mg) film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O5">
            <title>BI 1026706 – Tablet 400 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 400 mg (4x100 mg) film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O6">
            <title>BI 1026706 - Solution 10 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 10 mg solution under fasted condition.</description>
          </group>
          <group group_id="O7">
            <title>BI 1026706 - Solution 100 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 100 mg solution under fasted condition</description>
          </group>
          <group group_id="O8">
            <title>BI 1026706 - Solution 200 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 200 mg solution under fasted condition.</description>
          </group>
          <group group_id="O9">
            <title>BI 1026706 - Solution 400 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 400 mg solution under fasted condition.</description>
          </group>
          <group group_id="O10">
            <title>BI 1026706 - Solution 100 mg Fasted (R2)</title>
            <description>Subjects were treated with 100 mg drinking solution (R2) under fasting condition.</description>
          </group>
          <group group_id="O11">
            <title>BI 1026706 - 100 mg Solution Fed (T2)</title>
            <description>Subjects were treated with 100 mg drinking solution (T2) under fed condition.</description>
          </group>
          <group group_id="O12">
            <title>BI 1026706 - Tablet 100 mg Fasted (R1)</title>
            <description>Subjects were treated with 100mg film coated tablet (R1) under fasted condition.</description>
          </group>
          <group group_id="O13">
            <title>BI 1026706 - Tablet 100 mg Fed (T1)</title>
            <description>Subjects were treated with 100mg film coated tablet (T1) under fed condition.</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 (Terminal Half-life of the Analyte in Plasma)</title>
          <description>Terminal half-life of the analyte in plasma (t1/2).</description>
          <population>TS-SRD and TS-BA</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="11"/>
                <count group_id="O11" value="12"/>
                <count group_id="O12" value="12"/>
                <count group_id="O13" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.80" spread="75.7"/>
                    <measurement group_id="O2" value="8.58" spread="54.3"/>
                    <measurement group_id="O3" value="12.10" spread="26.6"/>
                    <measurement group_id="O4" value="11.60" spread="43.2"/>
                    <measurement group_id="O5" value="12.00" spread="22.7"/>
                    <measurement group_id="O6" value="13.90" spread="82.1"/>
                    <measurement group_id="O7" value="12.80" spread="54.7"/>
                    <measurement group_id="O8" value="11.50" spread="50.3"/>
                    <measurement group_id="O9" value="9.29" spread="27.3"/>
                    <measurement group_id="O10" value="10.80" spread="36.0"/>
                    <measurement group_id="O11" value="11.10" spread="53.9"/>
                    <measurement group_id="O12" value="10.50" spread="46.9"/>
                    <measurement group_id="O13" value="12.60" spread="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>f t1-t2 (SRD-Part)</title>
        <description>Fraction of analyte eliminated in urine from the time point t1 (0h) to time point t2 (72h) (f t1-t2).</description>
        <time_frame>0-4, 4-8, 8-12, 12-24, 24-48, 48-72 hours</time_frame>
        <population>TS-SRD</population>
        <group_list>
          <group group_id="O1">
            <title>BI 1026706 - Tablet 25 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 25 mg film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>BI 1026706 - Tablet 50 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 50 mg (2x25 mg) film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O3">
            <title>BI 1026706 – Tablet 100 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 100 mg film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O4">
            <title>BI 1026706 – Tablet 200 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 200 mg (2x100 mg) film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O5">
            <title>BI 1026706 – Tablet 400 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 400 mg (4x100 mg) film coated tablet with 240 mL of water under fasted condition.</description>
          </group>
          <group group_id="O6">
            <title>BI 1026706 - Solution 10 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 10 mg solution under fasted condition.</description>
          </group>
          <group group_id="O7">
            <title>BI 1026706 - Solution 100 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 100 mg solution under fasted condition</description>
          </group>
          <group group_id="O8">
            <title>BI 1026706 - Solution 200 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 200 mg solution under fasted condition.</description>
          </group>
          <group group_id="O9">
            <title>BI 1026706 - Solution 400 mg (SRD - Part)</title>
            <description>Subjects were treated in the morning with one single oral dose of 400 mg solution under fasted condition.</description>
          </group>
        </group_list>
        <measure>
          <title>f t1-t2 (SRD-Part)</title>
          <description>Fraction of analyte eliminated in urine from the time point t1 (0h) to time point t2 (72h) (f t1-t2).</description>
          <population>TS-SRD</population>
          <units>Percentage</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.02" spread="21.1"/>
                    <measurement group_id="O2" value="2.75" spread="51.2"/>
                    <measurement group_id="O3" value="3.43" spread="33.4"/>
                    <measurement group_id="O4" value="1.95" spread="27.2"/>
                    <measurement group_id="O5" value="1.87" spread="45.3"/>
                    <measurement group_id="O6" value="3.97" spread="40.8"/>
                    <measurement group_id="O7" value="3.47" spread="23.9"/>
                    <measurement group_id="O8" value="3.82" spread="32.8"/>
                    <measurement group_id="O9" value="2.09" spread="7.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first dose of study medication upto 15 days after the day of last intake of study medication, upto 32 days for SRD Part and 30 days for BA Part.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>BI 1026706 - Tablet 25 mg (SRD - Part)</title>
          <description>Subjects were treated in the morning with one single oral dose of 25 mg film coated tablet with 240 mL of water under fasted condition.</description>
        </group>
        <group group_id="E2">
          <title>BI 1026706 - Tablet 50 mg (SRD - Part)</title>
          <description>Subjects were treated in the morning with one single oral dose of 50 mg (2x25 mg) film coated tablet with 240 mL of water under fasted condition.</description>
        </group>
        <group group_id="E3">
          <title>BI 1026706 – Tablet 100 mg (SRD - Part)</title>
          <description>Subjects were treated in the morning with one single oral dose of 100 mg film coated tablet with 240 mL of water under fasted condition.</description>
        </group>
        <group group_id="E4">
          <title>BI 1026706 – Tablet 200 mg (SRD - Part)</title>
          <description>Subjects were treated in the morning with one single oral dose of 200 mg (2x100 mg) film coated tablet with 240 mL of water under fasted condition.</description>
        </group>
        <group group_id="E5">
          <title>BI 1026706 – Tablet 400 mg (SRD - Part)</title>
          <description>Subjects were treated in the morning with one single oral dose of 400 mg (4x100 mg) film coated tablet with 240 mL of water under fasted condition.</description>
        </group>
        <group group_id="E6">
          <title>BI 1026706 - Solution 10 mg (SRD - Part)</title>
          <description>Subjects were treated in the morning with one single oral dose of 10 mg solution under fasted condition.</description>
        </group>
        <group group_id="E7">
          <title>BI 1026706 - Solution 100 mg (SRD - Part)</title>
          <description>Subjects were treated in the morning with one single oral dose of 100 mg solution under fasted condition.</description>
        </group>
        <group group_id="E8">
          <title>BI 1026706 - Solution 200 mg (SRD - Part)</title>
          <description>Subjects were treated in the morning with one single oral dose of 200 mg solution under fasted condition.</description>
        </group>
        <group group_id="E9">
          <title>BI 1026706 - Solution 400 mg (SRD - Part)</title>
          <description>Subjects were treated in the morning with one single oral dose of 400 mg solution under fasted condition.</description>
        </group>
        <group group_id="E10">
          <title>Placebo (SRD - Part)</title>
          <description>Subjects were treated in the morning with one single oral dose of matching placebo tablet and also matching placebo solution with 240 mL of water under fasted condition.</description>
        </group>
        <group group_id="E11">
          <title>BI 1026706 - Solution 100 mg Fasted (R2)</title>
          <description>Subjects were treated with 100 mg drinking solution (R2) under fasting condition.</description>
        </group>
        <group group_id="E12">
          <title>BI 1026706 - 100 mg Solution Fed (T2)</title>
          <description>Subjects were treated with 100 mg drinking solution (T2) under fed condition.</description>
        </group>
        <group group_id="E13">
          <title>BI 1026706 - Tablet 100 mg Fasted (R1)</title>
          <description>Subjects were treated with 100mg film coated tablet (R1) under fasted condition.</description>
        </group>
        <group group_id="E14">
          <title>BI 1026706 - Tablet 100 mg Fed (T1)</title>
          <description>Subjects were treated with 100mg film coated tablet (T1) under fed condition.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Tendon pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim, Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

